Antisense - Kampf dem Krebs Video
Recent Police Force News:
Related Videos:
Leaders from Drug Delivery Industry to Discuss Advances in Biotech, Nanotech and Targeted Delivery Technologies at Arrowhead's 3rd Annual Drug D
Arrowhead's 3rd Annual Drug Delivery Summit, scheduled to take place in San Francisco, CA on May 14th and May 15th, 2009, will be bringing together leaders from the drug delivery industry to discuss the newest and most important advances being made in the field of drug delivery.
Arrowhead Releases New Report Assessing State of Personalized Medicine Market
The era of Personalized Medicine is set to revolutionize the healthcare industry. As our knowledge of genetics and molecular biology rapidly expands, a personalized approach to medical care is becoming increasingly important.
US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications
Patent Protection extends at least to 2025
Global Prostate Cancer Therapeutics Market to Reach $4.8 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Development of new therapies and drugs for prostate cancer is likely to supplement, rather substitute the prevailing drugs or therapies, such as chemotherapy, radiation therapy, hormonal therapy and surgery, and propel sales in global prostate cancer therapeutics market to $4.8 billion by 2015.
Global Rheumatoid Arthritis Therapeutics Market to Exceed $23.12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on Rheumatoid Arthritis Therapeutics markets. The world market for rheumatoid arthritis biologic therapeutics is projected to exceed $23.12 billion by 2015. The market comprises of a sizeable, growing patient population encompassing untreated patients, patients taking DMARDs, patients taking anti-TNF therapies, and patients taking non-anti-TNF therapies. Among all therapies, anti-pro-inflammatory drugs that block the action of TNF-alpha (known as anti-TNF biologics) dominate the market.
Global Dyslipidemia Therapeutics Market to Exceed $28 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
GIA announces the release of global report on Dyslipidemia Therapeutics market. The world market for Dyslipidemia Therapeutics is projected to exceed $28 billion by the year 2015. One of the key factors propelling the growth of anti-dyslipidemic drug market is aging population and the rising population of hypercholesterolemia patients.
First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy
Researchers from Children's National Medical Center and colleagues in Tokyo publish results, video of first successful trial in dogs with Duchenne muscular dystrophy
Ryogen is Awarded Patents on Two Human Genes
Ryogen LLC is awarded two U.S. Patent Nos. 7,468,266, titled "Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2," and 7,470,522 , titled "Isolated genomic polynucleotide fragments encoding human resistin and the human syntaxin binding protein 2.
antisensedrugs.com
The antisense drug resource
adultstemcell.org
The adult stem cell forum
